Hypothesis

Low‑dose berberine reprograms the senescence‑associated secretory phenotype (SASP) of existing senescent cells, shifting their secretome from a chronic inflammatory profile to a tissue‑repair‑biased, tumor‑suppressive profile through two convergent mechanisms: (1) direct AMPK activation and mTOR inhibition within senescent cells, which attenuates NF‑κB‑driven IL‑6/IL‑8 production; and (2) berberine‑induced expansion of gut Akkermansia and Bacteroides that elevates circulating butyrate, which acts as an HDAC inhibitor to enhance FOXO1‑mediated transcription of TGF‑β1 and other repair factors. Consequently, senescent cells continue to emit protective signals that restrain hyperplasia and promote wound healing while reducing the deleterious SASP components that drive inflammaging and fibrosis.

Testable Predictions

1. SASP re‑direction – In aged mice treated with berberine (0.2 % w/w in diet for 8 weeks), flow‑sorted p16^INK4a^+ senescent cells from liver and skin will show a ≥2‑fold increase in TGF‑β1 secretion and a ≥50 % decrease in IL‑6 and IL‑8 secretion compared with vehicle controls (ELISA).
2. AMPK/mTOR dependence – The SASP shift will be abrogated in senescent cells isolated from AMPKα1/α2 double‑knockout mice or when co‑treated with the mTOR activator MHY1485, confirming the intracellular pathway.
3. Microbiome mediation – Germ‑free mice receiving berberine will fail to exhibit the SASP shift, whereas fecal microbiota transplantation from berberine‑treated donors into antibiotic‑treated recipients will restore the TGF‑β1‑rich SASP profile.
4. Functional outcome – Berberine‑treated aged mice will display accelerated full‑thickness wound closure (≈30 % faster re‑epithelialization at day 7) and reduced collagen deposition (hydroxyproline content ↓40 %) relative to controls, without increasing hyperplasia or tumorigenesis in a carcinogen‑challenged skin model.

Mechanistic Rationale

Berberine’s rapid phosphorylation of AMPK at Thr172 (3) suppresses mTORC1 activity, a known regulator of SASP composition (2). AMPK activation also phosphorylates and inhibits IKKβ, dampening NF‑κB nuclear translocation and thus lowering IL‑6/IL‑8 transcription. Parallel to this, berberine remodels the gut microbiome, expanding butyrate‑producing taxa (4). Butyrate enters the circulation and inhibits class I HDACs, leading to hyperacetylation of FOXO1, which promotes its transcriptional activity on the TGF‑β1 promoter and other anti‑fibrotic genes. The combined intracellular signaling (AMPK/mTOR/NF‑κB) and extracellular epigenetic cue (butyrate/HDAC/FOXO1) creates a bistable switch in senescent cells: the SASP is tilted toward TGF‑β1‑dominant, repair‑oriented signaling while the pro‑inflammatory arm is restrained.

Experimental Design

• Animals: 20‑month‑old C57BL/6J mice (n=10/group) and matched AMPKα1/α2 DKO controls.
• Interventions: Berberine diet (0.2 %); vehicle control; berberine + MHY1485 (mTOR activator); berberine in germ‑free mice; fecal transplant from berberine‑treated donors into antibiotic‑treated recipients.
• Readouts: SASP cytokine profiling (multiplex ELISA) of FACS‑sorted p16^INK4a^+ cells; colonic microbiota sequencing (16S rRNA); serum butyrate (GC‑MS); wound healing assay (full‑thickness dorsal excisions); histology for collagen and proliferation (Ki‑67); tumor incidence after DMTPA treatment.
• Analysis: Two‑way ANOVA with post‑hoc Tukey; significance set at p<0.05.

Potential Impact

If validated, this hypothesis would reposition berberine not as a senolytic but as a "SASP modulator" that fine‑tunes the hostage‑negotiation function of senescent cells, offering a pharmacologic strategy to preserve their tumor‑suppressive and reparative roles while mitigating inflammaging. It would also provide a mechanistic bridge between mitochondrial signaling, microbiome metabolites, and cellular senescence, opening combinatorial avenues for age‑related disease intervention.